DOYLESTOWN, Pa., Nov. 16, 2016 /PRNewswire/ -- Atrin Pharmaceuticals, LLC. today announced the election of Jeffrey M. Dayno, M.D., chief medical officer of Egalet Corporation, to the Atrin Board of Directors.
"Dr. Jeffrey Dayno joins the Atrin board with an 18 year track record of success building and leading clinical development and medical affairs teams at both global and emerging biopharmaceutical companies," said Oren Gilad, Ph.D., Atrin Pharmaceuticals President and Chief Executive Officer. "Jeff brings to our board a keen perspective on all aspects of pharmaceutical medicine, including clinical development strategy and trial design, as well as regulatory strategy and experience interacting with the FDA, that will serve our company well as we prepare to advance our novel ATR inhibitors into clinical development. I am very pleased to welcome Jeff to the Atrin Board of Directors."
Prior to joining Egalet, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for pain and other conditions, Dr. Dayno was vice president, global medical affairs at ViroPharma, Inc., where he was also involved in early stage development for rare diseases. Prior to ViroPharma, Dr. Dayno served as the chief medical officer at Labopharm, Inc., a drug delivery technology company based in Montreal, Canada, where he first started working in the field of abuse-deterrent opioid product development. Before Labopharm, he was vice president of global medical affairs at Cephalon, Inc., and established the Phase 3B/4 late stage clinical development program. Dr. Dayno started his career in the pharmaceutical industry in 1998 at Merck & Co., Inc., where he spent 7 years in positions of increasing responsibility in the medical and scientific affairs division. Before moving into leadership roles in the pharmaceutical and biotechnology industry, he spent 10 years in academic and clinical medicine, involved in patient care, teaching, and clinical research. Dr. Dayno earned his medical degree from Temple University School of Medicine, completed his residency in Neurology at Temple University Hospital, and did a fellowship in Stroke and Cerebrovascular Disorders at Henry Ford Hospital. He is a former Chairman of the Philadelphia Stroke Council and, since 2014, has been a member of the Board of Visitors of the Lewis Katz School of Medicine at Temple University.
About Atrin Pharmaceuticals
Atrin Pharmaceuticals is a privately held biopharmaceutical company, based in Doylestown, PA, that aims to change the way cancer is being treated. The company is engaged in the discovery and development of innovative treatments for cancer. Atrin's most advanced program is focused on a new class of compounds that are highly specific inhibitors of ATR, a key mediator of DNA repair. Atrin is further assembling a pipeline of additional drug candidates, identified via the company's proprietary, human cell-based, high-throughput screening platform, Atrize™. Applicable to both drug discovery/development and the evaluation of patient-specific treatments, Atrize enables the rapid identification and evaluation of compounds that are effective in inhibiting cancer cell viability without adversely affecting healthy cells. For more information on the company, please visit our website at http://atrinpharma.com/.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atrin-pharmaceuticals-elects-jeffrey-m-dayno-md-to-board-of-directors-300363790.html
SOURCE Atrin Pharmaceuticals